AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2890951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2500
Study 29295035 — intervention group
Group type: EXPERIMENTAL
Intervention: Domestic violence (any type)
Number of subjects: 1883
Study 29295035 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlling behavior
Number of subjects: 1883
Study 29295035 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional violence
Number of subjects: 1883
Study 29295035 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual violence
Number of subjects: 1883
Study 29295035 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical violence
Number of subjects: 1883
Study 29295035 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age (30 to 40 years)
Number of subjects: 1883
Study 29295035 — intervention group
Group type: EXPERIMENTAL
Intervention: Age (41 to 50 years)
Number of subjects: 1883
Study 29295035 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of emotional support
Number of subjects: 1883
Study 29295035 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of tangible support
Number of subjects: 1883
Study 29295035 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived poor self-health
Number of subjects: 1883
Study 29295035 — intervention group
Group type: EXPERIMENTAL
Intervention: Husbands' poor health
Number of subjects: 1883
Study 29295035 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygamy
Number of subjects: 1883
Study 30882475 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway closure group
Number of subjects: 50
Study 30882475 — intervention group
Group type: COMPARATOR
Intervention: Matched control group
Number of subjects: 50
Study 27142099 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound imaging
Number of subjects: 50
Study 27142099 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopy imaging
Number of subjects: 50
Study 24957485 — intervention group
Group type: COMPARATOR
Intervention: safflower oil (HL) 51.7 kcal
Number of subjects: 13
Study 24957485 — intervention group
Group type: EXPERIMENTAL
Intervention: high-dose casein (HP) 51.7 kcal
Number of subjects: 13
Study 24957485 — intervention group
Group type: EXPERIMENTAL
Intervention: high-dose sucrose (HC) 51.7 kcal
Number of subjects: 13
Study 24957485 — intervention group
Group type: EXPERIMENTAL
Intervention: low-dose casein (LP) 17.2 kcal
Number of subjects: 13
Study 24957485 — intervention group
Group type: EXPERIMENTAL
Intervention: low-dose sucrose (LC) 17.2 kcal
Number of subjects: 13
Study 24957485 — intervention group
Group type: COMPARATOR
Intervention: control (C) saline
Number of subjects: 13
Study 24112417 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-week intensive intervention including breastfeeding benefits, understanding GDM, nutrition and exercise education, coping skills training, physical activity, educational and motivational text messaging, and 3 months of continued monthly contact
Number of subjects: 100
Study 24112417 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-week intensive intervention
Number of subjects: 100
Study 24112417 — intervention group
Group type: COMPARATOR
Intervention: Wait-listed control group
Number of subjects: 100
Study 21509429 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (1 mA for 20 minutes)
Number of subjects: 20
Study 21509429 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS (1 mA for 20 minutes)
Number of subjects: 20
Study 21509429 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (20 minutes)
Number of subjects: 20
Study 21509429 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 20
Study 19632943 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed/carboplatin/bevacizumab induction followed by pemetrexed/bevacizumab maintenance
Number of subjects: 900
Study 19632943 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel/carboplatin/bevacizumab induction followed by bevacizumab maintenance
Number of subjects: 900
Study 17980497 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropin Releasing Hormone analogue (GnRHa) treatment
Number of subjects: 15
Study 17980497 — intervention group
Group type: COMPARATOR
Intervention: Control group (wait-listed volunteers)
Number of subjects: 15
Study 15073842 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 0
Study 15073842 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan/5‐FU/LV
Number of subjects: 0
Study 15073842 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin/5‐FU/LV
Number of subjects: 0
Study 15073842 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan and oxaliplatin in combination with infusional 5‐FU/LV
Number of subjects: 0
Study 11842947 — intervention group
Group type: EXPERIMENTAL
Intervention: NaHCO3 2 mmol/kg/d for 7 days
Number of subjects: 149
Study 11842947 — intervention group
Group type: EXPERIMENTAL
Intervention: NaCl 2 mmol/kg/d for 7 days
Number of subjects: 149
Study 11842947 — intervention group
Group type: COMPARATOR
Intervention: No special therapy
Number of subjects: 149
Study 11842947 — intervention group
Group type: COMPARATOR
Intervention: Modification of mineral content of standard preterm formula
Number of subjects: 149
Study 9379066 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan 90 mg
Number of subjects: 10
Study 9379066 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 10
Study 8094308 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony stimulating factor (GM-CSF) at a starting dose of 250 micrograms/m2/day as continuous infusion via the IVC catheter.
Number of subjects: 66
Study 8094308 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (325 mg daily) given to both groups.
Number of subjects: 66
Study 8094308 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical clot aspiration used for occlusions during GM-CSF therapy.
Number of subjects: 66
Study 3666667 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine 2 X 25 mg
Number of subjects: 250
Study 3666667 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine 2 X 50 mg
Number of subjects: 250
Study 3666667 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 250
Study 30139501 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation (CA)
Number of subjects: 36
Study 30139501 — intervention group
Group type: COMPARATOR
Intervention: Medical rate control
Number of subjects: 36
Study 26808077 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar drain (LD) placement in Group A
Number of subjects: 60
Study 26808077 — intervention group
Group type: COMPARATOR
Intervention: Conservative management (bed rest and head elevation) in Group B
Number of subjects: 60
Study 24400920 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 30
Study 24400920 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 30
Study 24250451 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-midazolam
Number of subjects: 40
Study 24250451 — intervention group
Group type: COMPARATOR
Intervention: Propofol-fentanyl
Number of subjects: 40
Study 20228638 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevention care manager‐tailored telephone support intervention
Number of subjects: 38
Study 18398809 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification (LSM)
Number of subjects: 0
Study 18398809 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (MET)
Number of subjects: 0
Study 18398809 — intervention group
Group type: EXPERIMENTAL
Intervention: LSM + MET
Number of subjects: 0
Study 18398809 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 15971252 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week prevention program conducted by trained teachers
Number of subjects: 141
Study 15971252 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 141
Study 11991780 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-arm trained group
Number of subjects: 34
Study 11991780 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-arm trained group
Number of subjects: 34
Study 11991780 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal rotation
Number of subjects: 34
Study 11991780 — intervention group
Group type: EXPERIMENTAL
Intervention: External rotation
Number of subjects: 34
Study 10609068 — intervention group
Group type: COMPARATOR
Intervention: Single DMARD (methotrexate 7.5‐15 mg/week or sulfasalazine 1‐2 g/day or hydroxychloroquine 200 mg/day)
Number of subjects: 180
Study 10609068 — intervention group
Group type: COMPARATOR
Intervention: Combination of MTX + SSZ or MTX + HCQ
Number of subjects: 180
Study 10609068 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of MTX + SSZ + HCQ
Number of subjects: 180
Study 7492036 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg of IM ketorolac and oral placebo
Number of subjects: 20
Study 7492036 — intervention group
Group type: COMPARATOR
Intervention: 50 mg of oral indomethacin and IM placebo
Number of subjects: 20
Study 1600964 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone 0.375 micrograms kg‐1 min‐1
Number of subjects: 99
Study 1600964 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone 0.5 micrograms kg‐1 min‐1
Number of subjects: 99
Study 1600964 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone 0.75 micrograms kg‐1 min‐1
Number of subjects: 99
Study 1600964 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone (all dosages)
Number of subjects: 99
Study 6374497 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa (supplemental dopamine in precursor form)
Number of subjects: 0
Study 6374497 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study 30204516 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg·kg‐1)
Number of subjects: 13
Study 30204516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 30204516 — intervention group
Group type: EXPERIMENTAL
Intervention: Torque factor (Toptimal)
Number of subjects: 13
Study 30204516 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint duration (10 s)
Number of subjects: 13
Study 30143033 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care plus pharmacist-managed diabetes clinic (SOC + PMDC)
Number of subjects: 0
Study 30143033 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 0
Study 24619484 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficulties in Emotion Regulation Scale (DERS)
Number of subjects: 80
Study 24619484 — intervention group
Group type: EXPERIMENTAL
Intervention: DERS goals subscale
Number of subjects: 80
Study 24619484 — intervention group
Group type: EXPERIMENTAL
Intervention: DERS subscales
Number of subjects: 80
Study 22289212 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored intervention programme aimed at improving (vigorous) physical activity levels and healthy dietary behaviour, including tailored information, face‐to‐face and telephone counselling, training instruction, and various health-promoting materials.
Number of subjects: 0
Study 19157609 — intervention group
Group type: EXPERIMENTAL
Intervention: RA2 (double modulated arcs with RapidArc technique)
Number of subjects: 29
Study 19157609 — intervention group
Group type: EXPERIMENTAL
Intervention: RA1 (single modulated arcs with RapidArc technique)
Number of subjects: 29
Study 19157609 — intervention group
Group type: COMPARATOR
Intervention: IMRT (conventional fixed field IMRT)
Number of subjects: 29
Study 19157609 — intervention group
Group type: EXPERIMENTAL
Intervention: RA1
Number of subjects: 29
Study 19157609 — intervention group
Group type: EXPERIMENTAL
Intervention: RA2
Number of subjects: 29
Study 19157609 — intervention group
Group type: COMPARATOR
Intervention: IMRT
Number of subjects: 29
Study 17674028 — intervention group
Group type: COMPARATOR
Intervention: Pulsed electromagnetic fields (PEMF) at 0.005 T/s
Number of subjects: 32
Study 17674028 — intervention group
Group type: COMPARATOR
Intervention: Pulsed electromagnetic fields (PEMF) at 0.03 T/s
Number of subjects: 32
Study 17674028 — intervention group
Group type: COMPARATOR
Intervention: Pulsed electromagnetic fields (PEMF) at 0.09 T/s
Number of subjects: 32
Study 17674028 — intervention group
Group type: COMPARATOR
Intervention: Pulsed electromagnetic fields (PEMF) at varying intensities
Number of subjects: 32
Study 17674028 — intervention group
Group type: COMPARATOR
Intervention: Placebo (zero intensity)
Number of subjects: 32
Study 15611975 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 70 mg/m² on Days 1 and 8, carboplatin AUC 5 on Day 1, gemcitabine 1000 mg/m² on Days 1 and 8 every 21 days for a maximum of 8 cycles
Number of subjects: 32
Study 15611975 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel, carboplatin, and gemcitabine
Number of subjects: 32
Study 11896773 — intervention group
Group type: EXPERIMENTAL
Intervention: 1064 nm Nd:YAG laser
Number of subjects: 30
Study 11896773 — intervention group
Group type: COMPARATOR
Intervention: 810 nm diode laser
Number of subjects: 30
Study 11896773 — intervention group
Group type: COMPARATOR
Intervention: 755 nm alexandrite laser
Number of subjects: 30
Study 9681077 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPOMEt (weekly regimen incorporating cyclophosphamide, doxorubicin, vincristine, prednisone, methotrexate, and etoposide)
Number of subjects: 381
Study 9681077 — intervention group
Group type: COMPARATOR
Intervention: CHOP‐Mtx (cyclical regimen of cyclophosphamide, doxorubicin, vincristine, prednisone, and methotrexate)
Number of subjects: 381
Study 9681077 — intervention group
Group type: COMPARATOR
Intervention: CHOP‐Mtx
Number of subjects: 381
Study 9681077 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPOMEt
Number of subjects: 381
Study 7999849 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with rifampin and bacitracin
Number of subjects: 0
Study 7999849 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 0
Study 2967829 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioxaglate meglumine/sodium
Number of subjects: 126
Study 2967829 — intervention group
Group type: EXPERIMENTAL
Intervention: Iohexol
Number of subjects: 126
Study 2967829 — intervention group
Group type: COMPARATOR
Intervention: Diatrizoate meglumine/sodium
Number of subjects: 126
Study 30301241 — intervention group
Group type: COMPARATOR
Intervention: Control drink (450 mL; 2 kcal)
Number of subjects: 13
Study 30301241 — intervention group
Group type: EXPERIMENTAL
Intervention: M280 (14 g protein, 28 g carbohydrate, 12.4 g fat; 280 kcal)
Number of subjects: 13
Study 30301241 — intervention group
Group type: EXPERIMENTAL
Intervention: M504 (70 g protein, 28 g carbohydrate, 12.4 g fat; 504 kcal)
Number of subjects: 13
Study 30301241 — intervention group
Group type: EXPERIMENTAL
Intervention: P280 (70 g protein, 0 g carbohydrate, 0 g fat; 280 kcal)
Number of subjects: 13
Study 28177172 — intervention group
Group type: EXPERIMENTAL
Intervention: VIBRANT capsule treatment for 8 weeks
Number of subjects: 24
Study 28177172 — intervention group
Group type: COMPARATOR
Intervention: Sham capsule treatment for 8 weeks
Number of subjects: 24
Study 28177172 — intervention group
Group type: EXPERIMENTAL
Intervention: VIBRANT capsule treatment
Number of subjects: 24
Study 28177172 — intervention group
Group type: COMPARATOR
Intervention: Sham capsule treatment
Number of subjects: 24
Study 26299292 — intervention group
Group type: EXPERIMENTAL
Intervention: Bounce Back Now (BBN)
Number of subjects: 2000
Study 23987000 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,3-beta-D glucanase detection in plasma
Number of subjects: 37
Study 23987000 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients who underwent endoscopic surgery excluding fungal rhinosinusitis)
Number of subjects: 37
Study 23987000 — intervention group
Group type: COMPARATOR
Intervention: Comparison between case and control groups
Number of subjects: 37
Study 21389338 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-bias modification (CBM) intervention with avoidance movements (pushing a joystick) in response to alcohol pictures
Number of subjects: 214
Study 21389338 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-bias modification (CBM) intervention
Number of subjects: 214
Study 21389338 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (no training or sham training)
Number of subjects: 214
Study 19031710 — intervention group
Group type: EXPERIMENTAL
Intervention: Colon purification treatment
Number of subjects: 117
Study 19031710 — intervention group
Group type: COMPARATOR
Intervention: Routine anti‐coma hepaticum treatments
Number of subjects: 117
Study 16362397 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose intravenous metronidazole 500 mg preoperatively
Number of subjects: 50
Study 16362397 — intervention group
Group type: COMPARATOR
Intervention: Broad-spectrum multi-drug regimen (cefuroxime 1.5 g i.v. and metronidazole 0.5 g i.v. preoperatively, co-amoxiclav 375 mg orally 8-hourly postoperatively for 5 days)
Number of subjects: 50
Study 12921453 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalexin twice daily
Number of subjects: 271
Study 12921453 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalexin three times daily
Number of subjects: 271
Study 12921453 — intervention group
Group type: COMPARATOR
Intervention: Cefadroxil once daily
Number of subjects: 271
Study 11029359 — intervention group
Group type: COMPARATOR
Intervention: Bleomycin instillation (60E) via a small-bore thoracostomy tube
Number of subjects: 36
Study 11029359 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracoscopic talc poudrage (5 g) under local anesthesia
Number of subjects: 36
Study 8970874 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadolinium-DTPA-BMA
Number of subjects: 0
Study 8970874 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadolinium-HP-DO3A
Number of subjects: 0
Study 8970874 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadolinium-DTPA
Number of subjects: 0
Study 1303855 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil/promazine
Number of subjects: 40
Study 1303855 — intervention group
Group type: COMPARATOR
Intervention: Meperidine/promazine
Number of subjects: 40
Study 2580156 — intervention group
Group type: EXPERIMENTAL
Intervention: RO 13‐6438 10 mg intravenously
Number of subjects: 12
Study 2580156 — intervention group
Group type: EXPERIMENTAL
Intervention: RO 13‐6438 20 mg intravenously
Number of subjects: 12
Study 2580156 — intervention group
Group type: EXPERIMENTAL
Intervention: RO 13‐6438 20 mg orally
Number of subjects: 12
Study 2580156 — intervention group
Group type: EXPERIMENTAL
Intervention: RO 13‐6438 40 mg orally
Number of subjects: 12
Study 2580156 — intervention group
Group type: EXPERIMENTAL
Intervention: RO 13‐6438 60 mg orally
Number of subjects: 12
Study 2580156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31839089 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: periarticular injection of compound analgesics of ropivacaine, ketorolac, adrenaline, morphine and normal saline
Number of subjects: 134
Study 31839089 — intervention group
Group type: COMPARATOR
Intervention: Group B: periarticular injection of compound analgesics of bupivacaine, methylprednisolone, adrenaline, morphine and normal saline
Number of subjects: 134
Study 29481458 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected repetition duration (SELF)
Number of subjects: 12
Study 29481458 — intervention group
Group type: COMPARATOR
Intervention: Fixed repetition duration (FIX)
Number of subjects: 12
Study 27547890 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinal Nerve Fiber Layer Thickness (RNFLT)
Number of subjects: 181
Study 27547890 — intervention group
Group type: EXPERIMENTAL
Intervention: Bruch's Membrane Opening Minimum Rim Width (BMO‐MRW)
Number of subjects: 181
Study 27547890 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined parameter of RNFLT and BMO‐MRW
Number of subjects: 181
Study 24838902 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure therapy (10 cmH2O)
Number of subjects: 43
Study 24838902 — intervention group
Group type: COMPARATOR
Intervention: Placebo with null pressure
Number of subjects: 43
Study 22477065 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill exercise at 60% of VO(2max) for 90 min
Number of subjects: 7
Study 22477065 — intervention group
Group type: COMPARATOR
Intervention: Control trial (resting)
Number of subjects: 7
Study 20413372 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol plus betamethasone dipropionate gel
Number of subjects: 364
Study 20413372 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone dipropionate (single component in gel vehicle)
Number of subjects: 364
Study 20413372 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriol (single component in gel vehicle)
Number of subjects: 364
Study 20413372 — intervention group
Group type: COMPARATOR
Intervention: Gel vehicle alone
Number of subjects: 364
Study 17980928 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine with or without OADs
Number of subjects: 686
Study 17980928 — intervention group
Group type: EXPERIMENTAL
Intervention: Prandial insulin (once-daily, twice-daily, or more than twice-daily)
Number of subjects: 686
Study 16042796 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based health promotion and stress management training for six months
Number of subjects: 303
Study 16042796 — intervention group
Group type: COMPARATOR
Intervention: Reference group (no intervention)
Number of subjects: 303
Study 12270199 — intervention group
Group type: EXPERIMENTAL
Intervention: Onion intervention study measuring urinary quercetin levels
Number of subjects: 0
Study 12270199 — intervention group
Group type: EXPERIMENTAL
Intervention: LC‐PDA‐MS assay for dietary phytoestrogens
Number of subjects: 0
Study 10081632 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab (40 mg, 20 mg on days 0 and 4)
Number of subjects: 40
Study 7574046 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aprotinin (group A)
Number of subjects: 30
Study 7574046 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group C)
Number of subjects: 30
Study 2127562 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac potassium (50 mg 3-times daily)
Number of subjects: 108
Study 2127562 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam (20 mg once daily)
Number of subjects: 108
Study 2127562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108